The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
1. INTRODUCTION OF GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY DRUG CLASS
5.1. Overview
5.2. Opioids
5.3. NSAIDS
5.4. Local Anesthetics
5.5. Tricyclic Antidepressants
5.6. Antiepileptic Drugs
5.7. Others
6. GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.2. Oral
6.3. Intramuscular
6.4. Intravenous
6.5. Others
7. GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies
7.5. Others
8. GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY GEOGRAPHY
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Rest of Europe
8.4. Asia Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia Pacific
8.5. Rest of the World
9. GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Company Market Ranking
9.3. Key Development Strategies
10. COMPANY PROFILES
10.1. Mallinckrodt Pharmaceuticals.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
10.2. Trevena, Inc.
10.2.1. Overview
10.2.2. Financial Performance
10.2.3. Product Outlook
10.2.4. Key Developments
10.3. Heron Therapeutics
10.3.1. Overview
10.3.2. Financial Performance
10.3.3. Product Outlook
10.3.4. Key Developments
10.4. Pacira BioSciences.
10.4.1. Overview
10.4.2. Financial Performance
10.4.3. Product Outlook
10.4.4. Key Developments
10.5. Pfizer, Inc
10.5.1. Overview
10.5.2. Financial Performance
10.5.3. Product Outlook
10.5.4. Key Developments
10.6. Teva Pharmaceutical Industries Ltd.
10.6.1. Overview
10.6.2. Financial Performance
10.6.3. Product Outlook
10.6.4. Key Developments
10.7. Eli Lilly & Company.
10.7.1. Overview
10.7.2. Financial Performance
10.7.3. Product Outlook
10.7.4. Key Developments
10.8. Mallinckrodt Pharmaceuticals
10.8.1. Overview
10.8.2. Financial Performance
10.8.3. Product Outlook
10.8.4. Key Developments
10.9. Camarus
10.9.1. Overview
10.9.2. Financial Performance
10.9.3. Product Outlook
10.9.4. Key Developments
10.10. Novartis AG.
10.10.1. Overview
10.10.2. Financial Performance
10.10.3. Product Outlook
10.10.4. Key Developments
11. Appendix
11.1. Related Reports
| Price : US$ 3,500 | Date : Dec 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 167 |
| Price : US$ 3,500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 122 |
| Price : US$ 3,450 | Date : Oct 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 191 |
| Price : US$ 3,450 | Date : Oct 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 196 |
| Price : US$ 3,450 | Date : Oct 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 194 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
